Senseonics Holdings, Inc.

Senseonics Initiates First-in-Human Study of Freedom, Designed to be the World’s First CGM System with No On-body Component

Senseonics initiated a first-in-human early feasibility study of Freedom, an investigational one-year implantable CGM designed to communicate directly with a mobile device with no on-body transmitter. Freedom builds on the proven Eversense 365 sensing technology with an integrated battery and embedded Bluetooth; preclinical testing across roughly seven weeks and more than 18,500 communication data points showed 100% communication success for the preferred design. The study is intended to demonstrate safety and inform a pivotal study planned for 2027, with the company targeting a potential commercial launch in 2028.

•16h ago

Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas

Beta Bionics is partnering with Senseonics to integrate the Eversense 365 implantable continuous glucose monitor with the iLet Bionic Pancreas automated insulin delivery system, pairing year-long glucose sensing with fully adaptive insulin dosing. Development of the Eversense 365-iLet integration is expected to be completed during the fourth quarter of 2026, with commercial launch planned after testing, validation, and applicable regulatory requirements are satisfied. For Beta Bionics, the deal broadens CGM choice within the iLet ecosystem and strengthens its position in the automated insulin delivery category; no financial terms of the partnership were disclosed.

•1mo ago

Senseonics Holdings, Inc. Reports Second Quarter 2026 Financial Results

Senseonics reported Q2 2026 revenue of $14.5 million, representing 120% year-over-year growth, and raised full-year revenue guidance to $62 million-$66 million. Gross margin expanded to 59% compared to 47% in the prior year, driven by strong U.S. commercial momentum and the successful in-sourcing of European operations from Ascensia. The company strengthened its balance sheet during the quarter with over $100 million in gross proceeds, including approximately $90 million in equity and an expanded credit facility.

•2mo ago

Senseonics and Welldoc Partner to Develop Next-Generation App for Eversense® 365

Senseonics has partnered with Welldoc to develop a next-generation mobile app for its Eversense 365 implantable CGM system. The new app, expected to launch in the U.S. in the second half of 2026, will feature improved integration with Apple Health and Google Health Connect, alongside a revamped user interface for sensor pairing and data display. The collaboration leverages Welldoc’s AI-powered platform to potentially add features like CGM-informed bolus calculation and medication management in future updates, aiming to enhance patient retention and interoperability.

•4mo ago

SENS: 8-K · acquisition merger

Senseonics Holdings, Inc. announced the closing of its local asset purchase agreements for Eversense CGM commercial activities in Germany, Spain, and Sweden on June 1, 2026, with the Italy transaction closing on June 8, 2026. These transactions, originally disclosed in March 2026, involve the acquisition of assets and assumption of liabilities from Ascensia Diabetes Care Holdings AG, effectively expanding Senseonics' direct commercial presence in key European markets. The closings mark a significant operational milestone in the company's strategic partnership with Ascensia, allowing Senseonics to manage the commercialization of its continuous glucose monitoring technology in these regions directly.

SEC 8-K•4mo ago

Senseonics Enters Into Amended Loan Agreement with Hercules to Increase Borrowing Capacity to $140 Million

Hercules Capital entered into a Second Amendment with Senseonics to increase the borrowing capacity of its existing loan facility from $100 million to $140 million. The amendment provides for $20 million in near-term commitments split between a second tranche funded at closing and a third tranche expected May 6, 2026, with availability for up to $85 million in future tranches pending conditions. Senseonics indicated that combined with cash and recent equity proceeds, this expanded facility provides sufficient runway to fund operations into 2028.

•5mo ago